Literature DB >> 25824152

Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.

Kimberly A Birnie1, Yan Y Yip2, Dominic C H Ng3, Michaela B Kirschner4, Glen Reid4, Cecilia M Prêle5, Arthur W Bill Musk6, Y C Gary Lee7, Philip J Thompson7, Steven E Mutsaers5, Bahareh Badrian7.   

Abstract

UNLABELLED: Malignant pleural mesothelioma (MPM) is often fatal, and studies have revealed that aberrant miRNAs contribute to MPM development and aggressiveness. Here, a screen of miRNAs identified reduced levels of miR-223 in MPM patient specimens. Interestingly, miR-223 targets Stathmin (STMN1), a microtubule regulator that has been associated with MPM. However, whether miR-223 regulates STMN1 in MPM and the functions of miR-223 and STMN1 in this disease are yet to be determined. STMN1 is also regulated by c-Jun N-terminal kinase (JNK) signaling, but whether this occurs in MPM and whether miR-223 plays a role are unknown. The relationship between STMN1, miR-223, and JNK was assessed using MPM cell lines, cells from pleural effusions, and MPM tissue. Evidence indicates that miR-223 is decreased in all MPM tissue compared with normal/healthy tissue. Conversely, STMN1 expression was higher in MPM cell lines when compared with primary mesothelial cell controls. Following overexpression of miR-223 in MPM cell lines, STMN1 levels were reduced, cell motility was inhibited, and tubulin acetylation induced. Knockdown of STMN1 using siRNAs led to inhibition of MPM cell proliferation and motility. Finally, miR-223 levels increased while STMN1 was reduced following the re-expression of the JNK isoforms in JNK-null murine embryonic fibroblasts, and STMN1 was reduced in MPM cell lines following the activation of JNK signaling. IMPLICATIONS: miR-223 regulates STMN1 in MPM, and both are in turn regulated by the JNK signaling pathway. As such, miR-223 and STMN1 play an important role in regulating MPM cell motility and may be therapeutic targets. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25824152     DOI: 10.1158/1541-7786.MCR-14-0442

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  19 in total

1.  The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.

Authors:  Nancy S Vetter; E A Kolb; Christopher C Mills; Valerie B Sampson
Journal:  Mol Cancer Res       Date:  2017-03-08       Impact factor: 5.852

2.  A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Authors:  Jenette Creaney; Ian M Dick; Justine S Leon; Bruce W S Robinson
Journal:  Cancer Genomics Proteomics       Date:  2017 Mar-Apr       Impact factor: 4.069

3.  miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.

Authors:  Balabhadrapatruni V S K Chakravarthi; Darshan S Chandrashekar; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Satya S Pathi; Moloy T Goswami; Xiaojun Jing; Rui Wang; Rohit Mehra; Irfan A Asangani; Arul M Chinnaiyan; Upender Manne; Guru Sonpavde; George J Netto; Jennifer Gordetsky; Sooryanarayana Varambally
Journal:  Mol Cancer Res       Date:  2017-10-12       Impact factor: 5.852

4.  KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.

Authors:  Yuen Yee Cheng; Casey M Wright; Michaela B Kirschner; Marissa Williams; Kadir H Sarun; Vladimir Sytnyk; Iryna Leshchynska; J James Edelman; Michael P Vallely; Brian C McCaughan; Sonja Klebe; Nico van Zandwijk; Ruby C Y Lin; Glen Reid
Journal:  Mol Cancer       Date:  2016-06-01       Impact factor: 27.401

5.  miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

Authors:  Marissa Williams; Michaela B Kirschner; Yuen Yee Cheng; Jacky Hanh; Jocelyn Weiss; Nancy Mugridge; Casey M Wright; Anthony Linton; Steven C Kao; J James B Edelman; Michael P Vallely; Brian C McCaughan; Wendy Cooper; Sonja Klebe; Ruby C Y Lin; Himanshu Brahmbhatt; Jennifer MacDiarmid; Nico van Zandwijk; Glen Reid
Journal:  Oncotarget       Date:  2015-09-15

Review 6.  Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.

Authors:  Luigina Micolucci; Most Mauluda Akhtar; Fabiola Olivieri; Maria Rita Rippo; Antonio Domenico Procopio
Journal:  Oncotarget       Date:  2016-09-06

Review 7.  Roles of microRNAs in inflammatory bowel disease.

Authors:  HyunTaek Jung; Jae Seok Kim; Keum Hwa Lee; Kalthoum Tizaoui; Salvatore Terrazzino; Sarah Cargnin; Lee Smith; Ai Koyanagi; Louis Jacob; Han Li; Sung Hwi Hong; Dong Keon Yon; Seung Won Lee; Min Seo Kim; Paul Wasuwanich; Wikrom Karnsakul; Jae Il Shin; Andreas Kronbichler
Journal:  Int J Biol Sci       Date:  2021-05-17       Impact factor: 6.580

Review 8.  Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments.

Authors:  Rong Biaoxue; Cai Xiguang; Liu Hua; Yang Shuanying
Journal:  J Transl Med       Date:  2016-09-27       Impact factor: 5.531

9.  Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer.

Authors:  Akira Kurozumi; Yusuke Goto; Ryosuke Matsushita; Ichiro Fukumoto; Mayuko Kato; Rika Nishikawa; Shinichi Sakamoto; Hideki Enokida; Masayuki Nakagawa; Tomohiko Ichikawa; Naohiko Seki
Journal:  Cancer Sci       Date:  2015-12-05       Impact factor: 6.716

Review 10.  Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.

Authors:  Kimberly A Birnie; Cecilia M Prêle; Philip J Thompson; Bahareh Badrian; Steven E Mutsaers
Journal:  Oncotarget       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.